Biomarkers of therapeutic response in bladder cancer
Treatment of muscle-invasive bladder cancer (MIBC) typically includes systemic cisplatin-based chemotherapy. Despite being a mainstay first-line treatment for 3 decades, the response rate to this chemotherapy is only 50%. Genomic biomarkers of response are opportunities to improve cancer treatments, where specific therapies are selected because of patient’s individual traits. In this study, a combination of in vitro and clinical data are used to expand pharmacogenomics knowledge in MIBC in an attempt to lay the groundwork of biomarker identification with the goal to eventually influence patient ...
(For more, see "View full record.")